content: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
  Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  
  Date of Report (Date of earliest event reported)      December  3, 1996
  
                                       ENZON, INC.
               (Exact name of registrant as specified in its charter)
  
  
  
  Delaware                             0-12957              22-237286
  -------------------------------------------------------------------
  (State or other jurisdiction      (Commission          (IRS Employer
   of incorporation)                File Number)          Identification)
  
  
  
                  20 Kingsbridge Road, Piscataway, New Jersey 08854
                 (Address of principal executive offices) (Zip Code)
  
  
  
  Registrant's telephone number, including area code    (908) 980-4500
  
  
  
  
            (Former name or former address, if changed since last report)
  
  
  
  <PAGE>
  
  
  Item 5.  Other Events
  
                    Enzon,  Inc. (the "Enzon" or the  "Company")  announced at the
  1996 Annual Meeting of Shareholders  that under Enzon's agreement with the Green
  Cross  Corporation,  a Japanese  pharmaceutical  company,  for recombinant Human
  Serum  Albumin,  (rHSA) is currently in Phase III clinical  trials in Japan as a
  blood  volume  expander.  The  market  in Japan for rHSA is  approximately  $400
  million.  While  the  agreement  entitles  Enzon to a  customary  pharmaceutical
  royalty on product  sales,  Green Cross has requested  reduction of the royalty.
  Enzon is considering all its options under the agreement.
  
  
  
                                        - 2 -
  
  <PAGE>
  
  
  
                                     SIGNATURES
  
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
  
  
  
  Dated:  December 19, 1996
  
  
  
                                                                       ENZON, INC.
                                                                      (Registrant)
  
                                                     By:    /S/KENNETH J.ZUERBLIS
                                                               Kenneth J. Zuerblis
                                                           Vice President, Finance
                                                               and Chief Financial
                                                                           Officer
metadata_documents: [{"type": "8-K", "sequence": "1", "description": "FORM 8-K", "secsgml_size_bytes": 2575}]
metadata_filer: {"company-data": {"conformed-name": "ENZON INC", "cik": "0000727510", "assigned-sic": "2836", "irs-number": "222372868", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12957", "film-number": "96683707"}, "business-address": {"street1": "20 KINGSBRIDGE RD", "city": "PISCATAWAY", "state": "NJ", "zip": "08854", "phone": "9089804500"}, "mail-address": {"street1": "C/O ROSS & HARDIES", "street2": "65 EAST 55TH STREET", "city": "NEW YORK", "state": "NY", "zip": "10022-3219"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
  Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  
  Date of Report (Date of earliest event reported)      December  3, 1996
  
                                       ENZON, INC.
               (Exact name of registrant as specified in its charter)
  
  Delaware                             0-12957              22-237286
  -------------------------------------------------------------------
  (State or other jurisdiction      (Commission          (IRS Employer
   of incorporation)                File Number)          Identification)
  
                  20 Kingsbridge Road, Piscataway, New Jersey 08854
                 (Address of principal executive offices) (Zip Code)
  
  Registrant's telephone number, including area code    (908) 980-4500
  
            (Former name or former address, if changed since last report)
  Item 5.  Other Events
  
                    Enzon,  Inc. (the "Enzon" or the  "Company")  announced at the
  1996 Annual Meeting of Shareholders  that under Enzon's agreement with the Green
  Cross  Corporation,  a Japanese  pharmaceutical  company,  for recombinant Human
  Serum  Albumin,  (rHSA) is currently in Phase III clinical  trials in Japan as a
  blood  volume  expander.  The  market  in Japan for rHSA is  approximately  $400
  million.  While  the  agreement  entitles  Enzon to a  customary  pharmaceutical
  royalty on product  sales,  Green Cross has requested  reduction of the royalty.
  Enzon is considering all its options under the agreement.
  
                                        - 2 -
  SIGNATURES
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
  Dated:  December 19, 1996
  
                                                                       ENZON, INC.
                                                                      (Registrant)
  
                                                     By:    /S/KENNETH J.ZUERBLIS
                                                               Kenneth J. Zuerblis
                                                           Vice President, Finance
                                                               and Chief Financial
                                                                           Officer